Please ensure Javascript is enabled for purposes of website accessibility

Why Lexicon Pharmaceuticals Stock Is Down Today

By Prosper Junior Bakiny - Updated Jan 15, 2021 at 12:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A downgrade from an analyst might have something to do with it.

What happened?

After more than doubling in value on Thursday, shares of Lexicon Pharmaceuticals (LXRX -5.75%) are giving up some of those gains on Friday. The company's stock was down by 13.7% as of 12:39 p.m. EST today, after dropping by as much as 18.6% earlier in the day.

The company did not report any news today, but we can probably attribute these losses to two factors. First, it is plausible that some investors are choosing to take some profits after Lexicon's rally yesterday. Second, the stock was downgraded by a Wall Street analyst.

So what

It isn't every day that shares of a company rise by 105% in a mere 24-hour period, even in the highly volatile biotech industry. But on Thursday, Lexicon reported that it had received positive feedback from the Food and Drug Administration regarding one of its pipeline candidates.

The agency thinks the results from two phase 3 clinical trials for Lexicon's sotagliflozin can support a New Drug Application (NDA). The clinical trials in question investigated the cardiovascular efficacy of sotagliflozin in type-2 diabetes patients with worsening heart failure or with other heart-related ailments.

Downward-bound graph on a blackboard.

Image source: Getty Images.

After Thursday's rally, some of the company's investors probably saw an opportunity for a hefty profit. Elsewhere, Gabelli analyst Kevin Kedra downgraded Lexicon's stock to hold from buy. Kedra cited valuation concerns, which makes sense following the company's one-day surge.

It is also worth noting that Citigroup analyst Yigal Nochomovitz actually raised his price target for Lexicon to $13, up from $6, and kept a buy rating on the stock. Given that Lexicon's shares closed at $8.05 on Thursday, the analyst thinks there is even more upside left for the healthcare company.

Now what

What should investors make of all this noise? Not much, in my view. Following yesterday's good news, it is certainly worth keeping an eye on how things develop for Lexicon. But for those willing to pull the trigger now, even after Lexicon's shares more than doubled yesterday, it's important to remember that the company's stock will likely continue to be volatile. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$1.64 (-5.75%) $0.10
Citigroup Inc. Stock Quote
Citigroup Inc.
C
$49.32 (-3.39%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
328%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.